GlassScriptPhysician profile
Prathyusha Maddela
NPI 1437174448
$5,508.97
in general payments reported to CMS, 2019-2025
22 companies · $1,703 in 2025
The $1,703 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $299 · 2021: $697 · 2022: $748 · 2023: $802 · 2024: $996 · 2025: $1,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,292 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,291.55 |
| Education | $209.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $580.34 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $566.84 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Akebia Therapeutics INC | $557.04 | 2020-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $527.15 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $463.84 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $430.32 | 2020-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $380.81 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $374.52 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $350.30 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $268.44 | 2019-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $218.01 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $178.36 | 2021-2023 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $146.54 | 2022-2025 | Lupkynis |
| Horizon Therapeutics Plc | $117.31 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $97.26 | 2020-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.28 | 2024-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $65.38 | 2019 | |
| Ani Pharmaceuticals, INC. | $31.73 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $20.29 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.97 | 2022 | |
| Apellis Pharmaceuticals, INC. | $17.71 | 2025 | Empaveli |
| Shire North American Group INC | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prathyusha Maddela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.